Hal Martin

3.4k total citations · 1 hit paper
44 papers, 1.8k citations indexed

About

Hal Martin is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Hal Martin has authored 44 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Infectious Diseases, 32 papers in Virology and 18 papers in Emergency Medicine. Recurrent topics in Hal Martin's work include HIV/AIDS drug development and treatment (41 papers), HIV Research and Treatment (32 papers) and HIV/AIDS Research and Interventions (20 papers). Hal Martin is often cited by papers focused on HIV/AIDS drug development and treatment (41 papers), HIV Research and Treatment (32 papers) and HIV/AIDS Research and Interventions (20 papers). Hal Martin collaborates with scholars based in United States, France and United Kingdom. Hal Martin's co-authors include Erin Quirk, Xuelian Wei, Andrew Cheng, Kirsten White, Indira Brar, Joseph M. Custodio, Paul E. Sax, Anthony Mills, Rima Acosta and Jürgen K. Rockstroh and has published in prestigious journals such as The Lancet, Gastroenterology and PLoS ONE.

In The Last Decade

Hal Martin

42 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

2017 257 citations Joel E. Gallant, Adriano Lazzarin et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hal Martin United States	21	1.6k	1.2k	838	252	135	44	1.8k
Jean van Wyk United Kingdom	18	930 0.6×	608 0.5×	345 0.4×	265 1.1×	67 0.5×	58	1.2k
Michael Aboud United Kingdom	13	950 0.6×	703 0.6×	407 0.5×	172 0.7×	55 0.4×	31	1.1k
Cynthia Brinson United States	18	1.3k 0.8×	1.0k 0.9×	449 0.5×	333 1.3×	118 0.9×	36	1.5k
Donnie McGrath United States	14	970 0.6×	683 0.6×	372 0.4×	154 0.6×	43 0.3×	19	1.1k
Joseph J. Eron United States	16	978 0.6×	734 0.6×	297 0.4×	186 0.7×	61 0.5×	29	1.1k
Antonio Antela Spain	18	678 0.4×	362 0.3×	330 0.4×	391 1.6×	193 1.4×	49	947
Cheryl McDonald United States	14	619 0.4×	431 0.4×	212 0.3×	154 0.6×	102 0.8×	27	769
Jennifer S Fusco United States	14	628 0.4×	378 0.3×	330 0.4×	195 0.8×	52 0.4×	57	843
Patricia W. H. Hugen Netherlands	19	973 0.6×	733 0.6×	163 0.2×	177 0.7×	74 0.5×	27	1.1k
Dan Duiculescu Romania	11	805 0.5×	628 0.5×	219 0.3×	225 0.9×	42 0.3×	22	949

Countries citing papers authored by Hal Martin

Since Specialization

Citations

This map shows the geographic impact of Hal Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hal Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hal Martin more than expected).

Fields of papers citing papers by Hal Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hal Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hal Martin. The network helps show where Hal Martin may publish in the future.

Co-authorship network of co-authors of Hal Martin

This figure shows the co-authorship network connecting the top 25 collaborators of Hal Martin. A scholar is included among the top collaborators of Hal Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hal Martin. Hal Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mounzer, Karam, Jihad Slim, Moti Ramgopal, et al.. (2024). Étude de phase 2 évaluant l'association BIC + LEN en prise orale quotidienne chez des personnes ayant un traitement du VIH par plusieurs comprimés. 3(2). S136–S136. 1 indexed citations

Orkin, Chloe, Andrea Antinori, Jürgen K. Rockstroh, et al.. (2024). Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy. AIDS. 38(7). 983–991. 5 indexed citations

Avihingsanon, Anchalee, Hongzhou Lu, Chee Loon Leong, et al.. (2023). 330 WEEK 48 RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) VS DOLUTEGRAVIR + EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (DTG+F/TDF) IN ART-NAIVE, HIV/HBV-COINFECTED ADULTS (ALLIANCE). Gastroenterology. 164(6). S–1241. 1 indexed citations

Avihingsanon, Anchalee, Ploenchan Chetchotisakd, Sasisopin Kiertiburanakul, et al.. (2022). Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials. HIV Medicine. 24(3). 290–300. 6 indexed citations

Maggiolo, Franco, Giuliano Rizzardini, Jean‐Michel Molina, et al.. (2022). Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age. HIV Medicine. 24(1). 27–36. 27 indexed citations

Rizzardini, Giuliano, Jean‐Michel Molina, Federico Pulido, et al.. (2021). Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infectious Diseases and Therapy. 10(2). 775–788. 40 indexed citations

Acosta, Rima, Madeleine Willkom, Kristen Andreatta, et al.. (2020). Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(3). 363–371. 20 indexed citations

Brar, Indira, Peter Ruane, Douglas Ward, et al.. (2020). 1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine. Open Forum Infectious Diseases. 7(Supplement_1). S543–S544. 3 indexed citations

Wohl, David A., Yazdan Yazdanpanah, Axel Baumgarten, et al.. (2019). Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 6(6). e355–e363. 116 indexed citations

10.

Stellbrink, Hans‐Jürgen, José Ramón Arribas, Jeffrey L. Stephens, et al.. (2019). Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 6(6). e364–e372. 99 indexed citations

11.

Daar, Eric S., Edwin DeJesus, Peter Ruane, et al.. (2018). Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 5(7). e347–e356. 117 indexed citations

12.

White, Kirsten, Will Garner, Joseph J. Eron, et al.. (2018). Repeat testing of low-level HIV-1 RNA. AIDS. 32(8). 1053–1057. 1 indexed citations

13.

Wohl, David A., Amanda Clarke, Franco Maggiolo, et al.. (2018). Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 11(5). 561–573. 41 indexed citations

14.

Molina, Jean‐Michel, Douglas Ward, Indira Brar, et al.. (2018). Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. The Lancet HIV. 5(7). e357–e365. 138 indexed citations

15.

Gallant, Joel E., Adriano Lazzarin, Anthony Mills, et al.. (2017). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. The Lancet. 390(10107). 2063–2072. 257 indexed citations breakdown →

16.

Zhang, Heather, Joseph M. Custodio, Xuelian Wei, et al.. (2017). P176 Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Sexually Transmitted Infections. 93(Suppl 1). A74.2–A74. 10 indexed citations

17.

Sax, Paul E., Edwin DeJesus, Gordon Crofoot, et al.. (2017). Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. The Lancet HIV. 4(4). e154–e160. 72 indexed citations

18.

DeJesus, Edwin, Anton Pozniak, Melanie Thompson, et al.. (2015). P031: Tenofovir alafenamide in a single-tablet regimen in initial HIV-1 therapy. Journal of the International AIDS Society. 18(3 (Suppl 2)). 9 indexed citations

19.

Mills, Anthony, Gordon Crofoot, Cheryl McDonald, et al.. (2015). Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(4). 439–445. 121 indexed citations

20.

Sax, Paul E., Andrew Zolopa, Indira Brar, et al.. (2014). Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(1). 52–58. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact